We are live on
!
Find out more
AG
Artal Group Portfolio holdings
AUM
$931M
1-Year Est. Return
41.63%
This Fund
S&P 500
This Quarter
Est. Return
+29.93%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.38B
AUM Growth
-$1.54B
(-39%)
Cap. Flow
-$2.1B
Cap. Flow
% of AUM
-88.13%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
112
New
–
Increased
–
Reduced
2
Closed
110
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CAVA Group
CAVA
|
+$610M |
| 2 |
Scholar Rock
SRRK
|
+$93.8M |
| 3 |
Kymera Therapeutics
KYMR
|
+$89.7M |
| 4 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$86.1M |
| 5 |
Arrowhead Research
ARWR
|
+$82.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 91.02% |
| 2 | Healthcare | 8.98% |
| 3 | Communication Services | 0% |
| 4 | Real Estate | 0% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Korro Bio
KRRO
$207M
| – | – |
-413,072
| Closed | -$14M |
|
52
Kura Oncology
KURA
$1.01B
| – | – |
-1,819,884
| Closed | -$37.5M |
|
53
Kenvue
KVUE
$34.4B
| – | – |
-137,000
| Closed | -$2.49M |
|
|
54
Kymera Therapeutics
KYMR
$9.41B
| – | – |
-3,005,610
| Closed | -$89.7M |
|
55
Lexeo Therapeutics
LXEO
$339M
| – | – |
-603,435
| Closed | -$9.68M |
|
56
MongoDB
MDB
$30.4B
| – | – |
-4,021
| Closed | -$1.01M |
|
57
Meta Platforms (Facebook)
META
$1.71T
| – | – |
-1,100
| Closed | -$555K |
|
|
DFTX
58
Definium Therapeutics
DFTX
$4.95B
| – | – |
-1,007,875
| Closed | -$7.27M |
|
|
MRUS
59
DELISTED
Merus
MRUS
| – | – |
-760,355
| Closed | -$45M |
|
60
Microsoft
MSFT
$3.69T
| – | – |
-11,300
| Closed | -$5.05M |
|
61
NewAmsterdam Pharma
NAMS
$2.53B
| – | – |
-800,000
| Closed | -$15.4M |
|
62
Neumora Therapeutics
NMRA
$156M
| – | – |
-2,824,052
| Closed | -$27.8M |
|
63
ServiceNow
NOW
$147B
| – | – |
-12,500
| Closed | -$1.97M |
|
64
NVIDIA
NVDA
$5.12T
| – | – |
-43,000
| Closed | -$5.31M |
|
65
Ovid Therapeutics
OVID
$529M
| – | – |
-2,500,000
| Closed | -$1.92M |
|
66
Palo Alto Networks
PANW
$307B
| – | – |
-9,000
| Closed | -$1.53M |
|
67
Procore
PCOR
$7.99B
| – | – |
-32,300
| Closed | -$2.14M |
|
68
Pinduoduo
PDD
$111B
| – | – |
-45,500
| Closed | -$6.05M |
|
69
Pegasystems
PEGA
$6.19B
| – | – |
-23,000
| Closed | -$696K |
|
70
PepGen
PEPG
$200M
| – | – |
-113,317
| Closed | -$1.81M |
|
71
Prothena Corp
PRTA
$428M
| – | – |
-1,001,360
| Closed | -$20.7M |
|
72
CALL
PayPal
PYPL
$46B
| – | – |
-26,000
| Closed | -$1.51M |
|
|
73
PayPal
PYPL
$46B
| – | – |
-15,000
| Closed | -$870K |
|
74
Qualcomm
QCOM
$201B
| – | – |
-7,500
| Closed | -$1.49M |
|
75
Ultragenyx Pharmaceutical
RARE
$1.29B
| – | – |
-275,000
| Closed | -$11.3M |
|
Similar funds
BCM
ACM
SAM
NS
PA
ACM
CICI
CAM
Artal Group's Q3 2024 Portfolio in Review
As of Q3 2024, Artal Group held 112 positions worth $2.38B, down 39% from $3.92B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Artal Group withdrew a net $2.1B in Q3 2024, closing 110 positions and reducing 2 holdings. Its most notable exit was Scholar Rock, an estimated $93.8M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 91% of assets, up from 56% a quarter earlier, followed by Healthcare and Communication Services.
- Artal Group's biggest Q3 2024 reduction was CAVA Group, cutting an estimated $610M.
- Artal Group fully exited Scholar Rock in Q3 2024, selling an estimated $93.8M.
- Artal Group's ten largest holdings make up 100% of its $2.38B portfolio in Q3 2024.
- Artal Group opened 0 new positions and closed 110 in Q3 2024.
- Artal Group's portfolio value fell 39% quarter-over-quarter to $2.38B.
Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.